Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H

被引：34

作者：

Cortelezzi, Agostino

Vigano, Mauro

Zilioli, Vittorio R.

Fantini, Norma N.

Pasquini, Maria C.

Deliliers, Giorgio Lambertenghi

Colombo, Massimo

Lampertico, Pietro

机构：

[1] IRCCS Fdn Osped Maggiore, Hematol Bone Marrow Transplantat Unit 1, I-20122 Milan, Italy

[2] Univ Milan, I-20122 Milan, Italy

[3] IRCCS Fdn Osped Maggiore, Dept Gastroenterol & Endocrinol, Milan, Italy

来源：

JOURNAL OF CLINICAL VIROLOGY | 2006年 / 35卷 / 04期

关键词：

HBV reactivation; lamivudine; adefovir dipivoxil; B-cell chronic lymphocytic leukemia; alemtuzumab;

D O I：

10.1016/j.jcv.2005.10.009

中图分类号：

Q93 [微生物学];

学科分类号：

071005 [微生物学]; 100705 [微生物与生化药学];

摘要：

We describe a case of severe reactivation of occult hepatitis B virus infection in a 49-year-old man, who was treated with high doses of chlorambucil for a Binet stage A B-cell chronic lymphocytic leukemia (B-CLL). The patient was initially treated with lamivudine and subsequently with lamivudine and adefovir dipivoxil combination therapy to control viral replication and allow for long-term anti-cancer chemotherapy with alemtuzumab (Campath-1H), which was introduced to rescue for a B-CLL relapse. During 20 months of anti-HBV therapy, ALT and HBV-DNA levels progressively declined and B-CLL was successfully kept under control by long-term alemtuzumab administration. (C) 2005 Elsevier B.V. All rights reserved.

引用

页码：467 / 469

页数：3

共 22 条

[1]

Ahmed A, 1999, AM J GASTROENTEROL, V94, P249, DOI 10.1111/j.1572-0241.1999.00808.x

[2]

Treatment of chronic hepatitis B virus infection in patients co-infected with human immunodeficiency virus [J].